CN
As a leading company in the pharmaceutical equipment industry, Xin Weisheng grandly launched its latest automatic rotary tablet press machine at the Beijing International Pharmaceutical Exhibition today. This tablet press, named "ZP-37B", is expected to bring revolutionary production efficiency improvements to the pharmaceutical industry with its excellent performance and innovative technology.
The ZP-37B automatic rotary tablet press adopts the most advanced automatic control system, which can achieve high-precision pressure regulation and speed control, greatly improving the consistency and accuracy of tableting. In addition, the machine is designed with a unique dual discharge system, which not only speeds up production, but also ensures that the quality of each tablet meets international pharmaceutical production standards.
Li Hua, general manager of Xin Weisheng, said at the press conference: "The launch of ZP-37B marks a solid step forward for our company in the field of automated tableting technology. We are committed to helping global pharmaceutical companies improve production efficiency and product quality through continuous technological innovation, and ultimately benefit a wider range of consumers."
It is understood that the ZP-37B automatic rotary tablet press has many innovative features, including an intelligent fault diagnosis system, an automatic cleaning mechanism and a modular design, making the equipment maintenance easier and faster. In addition, its environmentally friendly and energy-saving characteristics also make this model one of the most popular tablet presses on the market.
The new product launch of Xin Weisheng has attracted the attention of many industry experts and media. Industry experts believe that the launch of the ZP-37B automatic rotary tablet press not only improves the technical standards of pharmaceutical equipment, but also will drive the entire industry towards a more efficient and environmentally friendly direction.
With the growing demand for efficient production equipment in the global pharmaceutical industry, this innovative equipment from Xin Weisheng has undoubtedly opened up new market opportunities for companies. In the future, Xin Weisheng will continue to rely on its strong R&D capabilities to provide customers with more high-quality and efficient pharmaceutical solutions.
20 Apr 2025
Novartis to invest $23 billion in US manufacturing and research expansion
Find out more
